0I5P Stock Overview
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
CymaBay Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$32.48 |
| 52 Week High | US$32.51 |
| 52 Week Low | US$7.32 |
| Beta | 0.32 |
| 1 Month Change | 0.90% |
| 3 Month Change | 38.79% |
| 1 Year Change | 264.98% |
| 3 Year Change | 639.95% |
| 5 Year Change | n/a |
| Change since IPO | 179.07% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0I5P | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 0.1% | 3.3% | 2.7% |
| 1Y | 265.0% | -3.7% | 0.3% |
Return vs Industry: 0I5P exceeded the UK Pharmaceuticals industry which returned 0.7% over the past year.
Return vs Market: 0I5P exceeded the UK Market which returned 3.1% over the past year.
Price Volatility
| 0I5P volatility | |
|---|---|
| 0I5P Average Weekly Movement | 8.2% |
| Pharmaceuticals Industry Average Movement | 8.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0I5P's share price has been volatile over the past 3 months.
Volatility Over Time: 0I5P's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 101 | Sujal Shah | www.cymabay.com |
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes.
CymaBay Therapeutics, Inc. Fundamentals Summary
| 0I5P fundamental statistics | |
|---|---|
| Market cap | US$3.73b |
| Earnings (TTM) | -US$105.37m |
| Revenue (TTM) | US$31.07m |
120.0x
P/S Ratio-35.4x
P/E RatioIs 0I5P overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0I5P income statement (TTM) | |
|---|---|
| Revenue | US$31.07m |
| Cost of Revenue | US$80.80m |
| Gross Profit | -US$49.73m |
| Other Expenses | US$55.64m |
| Earnings | -US$105.37m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.92 |
| Gross Margin | -160.03% |
| Net Profit Margin | -339.10% |
| Debt/Equity Ratio | 37.4% |
How did 0I5P perform over the long term?
See historical performance and comparison